California Stem Cell, Cellular Biomedicine, NeoStem deal

NeoStem completed its acquisition of stem cell company California Stem Cell for 5.3 million shares, or about $24.5 million based on NeoStem's close of $4.59 on May 8, before the deal closed. California Stem Cell is also eligible for up to $90 million in milestones and royalties, payable in cash or shares (see BioCentury, April 21). ...